小分子疗法产品开发商Vividion Therapeutics宣布收购Tavros Therapeutic，以扩大功能基因组学能力并推动药物发现平台-动脉网

Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

拜耳等信源发布 2025-01-08 21:09



可切换为仅中文







January

一月

2025

14:00 PM

14：下午00点

Europe/Amsterdam

欧洲/阿姆斯特丹

Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

Vividion Therapeutics收购Tavros Therapeutics，以扩展功能基因组学能力并推动药物发现平台

Not intended for U.S. and UK Media

不适用于美国和英国媒体

Summary

摘要

Addition of Tavros will greatly expand target space reachable by Vividion / Acquisition builds on successful collaboration focused on promising drug targets in oncology

Tavros的加入将大大扩展Vividion/Acquisition可达到的目标空间，这是建立在成功合作的基础上，专注于肿瘤学中有前途的药物靶标

San Diego, CA, USA, Berlin, Germany and Durham, NC, USA, January 8, 2025

美国加利福尼亚州圣地亚哥、德国柏林和美国北卡罗来纳州达勒姆，2025年1月8日

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company.

Vividion Therapeutics，Inc.是一家临床阶段的生物制药公司，利用新的发现技术来解锁高价值，传统上不可药用的靶标，并开发用于破坏性癌症和免疫疾病的小分子精确疗法，今天宣布收购Tavros Therapeutics，Inc.，一家精确的肿瘤平台公司。

Vividion is a wholly owned and independently operating subsidiary of Bayer AG..

Vividion是拜耳公司的全资独立运营子公司。。

The addition of Tavros greatly expands Vividion’s functional genomics expertise and capabilities, bringing proprietary methods for genomic screening that can identify new target opportunities, as well as support discovery and translational efforts towards known targets. Combining the Tavros platform with Vividion’s chemoproteomics expertise and capabilities will greatly enhance Vividion’s efforts to generate potential best- and first-in-class drug targets across oncology and immunology. .

Tavros的加入极大地扩展了Vividion的功能基因组学专业知识和能力，为基因组筛选带来了专有方法，可以识别新的目标机会，并支持对已知目标的发现和转化努力。将Tavros平台与Vividion的化学蛋白质组学专业知识和能力相结合，将大大增强Vividion在肿瘤学和免疫学领域产生潜在的最佳和一流药物靶标的努力。。

Vividion and Tavros have been working together for the past two years under a strategic collaboration to discover and develop novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.

过去两年来，Vividion和Tavros在战略合作下一直在合作，以发现和开发能够解决传统小分子药物无法解决的致癌蛋白质的新型精确疗法。

“The addition of Tavros will expand and strengthen our chemoproteomics drug screening capabilities and open up a new target space to fuel the growing pipeline of novel therapies across oncology and immunology”, said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We have already seen the power of combining Vividion’s platform and compound library with Tavros’s functional genomics capabilities in uncovering druggable vulnerabilities in tumor cells.

Vividion首席执行官Aleksandra Rizo医学博士说：“Tavros的加入将扩大和加强我们的化学蛋白质组学药物筛选能力，并开辟一个新的目标空间，为肿瘤学和免疫学领域不断增长的新疗法提供燃料。”。“我们已经看到了将Vividion的平台和复合文库与Tavros的功能基因组学功能相结合的力量，可以发现肿瘤细胞中的药物漏洞。

We are excited to take this next step to unlock the full potential of our work together for the patients in need.”.

我们很高兴采取下一步行动，为有需要的患者释放我们共同工作的全部潜力。”。

“The acquisition of Tavros is an exciting next step as we seek to accelerate the development of previously undruggable targets to improve outcomes for patients with significant high unmet medical needs”, said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division.

拜耳制药部业务开发和许可主管Juergen Eckhardt医学博士表示：“收购Tavros是一个令人兴奋的下一步，因为我们寻求加速开发以前无法治愈的目标，以改善严重未满足医疗需求的患者的预后。”。

“It is also the first acquisition in the history of Bayer Pharmaceuticals for one of our ‘arms-length’ model companies, demonstrating the flexible operating model while Vividion continues to operate autonomously to drive breakthrough innovations in precision oncology and immunology.”.

“这也是拜耳制药历史上第一次收购我们的‘公平交易’模式公司之一，展示了灵活的运营模式，同时Vividion继续自主运营，推动精准肿瘤学和免疫学的突破性创新。”。

“We are thrilled for the opportunity to combine forces with Vividion. We have enjoyed a highly productive partnership over the past two years and have seen the clear synergy between our platforms”, said Eoin McDonnell, Ph.D., Chief Executive Officer and co-founder of Tavros. “We look forward to building on our success to date to develop novel small molecule therapeutics against elusive protein targets and maximize our ability to bring new treatment options to patients.”.

Tavros首席执行官兼联合创始人Eoin McDonnell博士表示：“我们很高兴有机会将力量与Vividion结合起来。过去两年来，我们建立了卓有成效的合作关系，并看到了我们平台之间的明显协同作用。”。“我们期待着在迄今为止取得成功的基础上，开发针对难以捉摸的蛋白质靶标的新型小分子疗法，并最大限度地提高我们为患者带来新治疗选择的能力。”。

Financial terms are not disclosed.

财务条款未披露。

About Tavros Therapeutics, Inc.

关于Tavros Therapeutics，Inc。

Tavros Therapeutics is a precision oncology platform company that leverages next-generation functional and computational genomics technology to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need. Modular, scalable and fast, the company’s next generation, bi-directional synthetic lethality platform can precisely and directly identify the paired genetic interactions that form the basis for breakthrough targets and first-in-class cancer drugs.

Tavros Therapeutics是一家精密肿瘤学平台公司，利用下一代功能和计算基因组学技术来发现肿瘤内的独特漏洞，以发现临床需求高度未满足领域的新靶点和生物标志物。该公司的下一代双向合成杀伤力平台具有模块化、可扩展性和快速性，可以准确直接地识别成对的遗传相互作用，这些相互作用构成了突破性目标和一流癌症药物的基础。

Cutting edge functional genomics and computational analysis accelerates the discovery of de-risked, druggable targets to improve patient outcomes, minimizing toxicity, and quickening development in defined patient subsets. Strategic partnerships with Zentalis Pharmaceuticals, OpenBench, Inc., and Vividion Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, have validated the platform and expanded the company’s clinical impact.

尖端的功能基因组学和计算分析加速了去风险，可药物靶标的发现，以改善患者预后，最大限度地减少毒性，并加快确定患者亚群的发展。与Zentalis Pharmaceuticals、OpenBench，Inc.和拜耳公司全资独立运营子公司Vividion Therapeutics的战略合作伙伴关系验证了该平台并扩大了该公司的临床影响力。

Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a highly innovative pipeline of category-defining small-molecule drug candidates. Based in Durham, N.C., management is comprised of successful serial entrepreneurs with deep expertise in functional genomics, tumor genetics, and drug discovery.

塔夫罗斯还利用其专有平台和有用的合成致命关系图，建立了一个高度创新的类别定义小分子候选药物管道。管理层总部位于北卡罗来纳州达勒姆，由在功能基因组学、肿瘤遗传学和药物发现方面拥有深厚专业知识的成功系列企业家组成。

To learn more, visit .

要了解更多信息，请访问。

www.tavrostx.com

About Vividion

关于Vividion

Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics，Inc.，拜耳公司的全资和独立运营子公司，是一家临床阶段的生物制药公司，利用新的发现技术来解锁高价值，传统上不可药用的目标，并为毁灭性癌症和免疫疾病提供精确治疗。

The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets.

该公司的平台使其能够在涉及多种疾病的经过充分验证的蛋白质靶标上识别数百个以前未知的功能口袋，同时从其专有的共价化学文库中识别与这些口袋高度选择性相互作用的化合物。

The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit .

该公司正在利用其专有的化学蛋白质组学平台，推进针对肿瘤学和免疫学中高价值，传统上不可药用靶标的高选择性小分子治疗剂的多样化管道。有关更多信息，请访问。

www.vividion.com

维维迪翁

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家全球性企业，在医疗保健和营养等生命科学领域拥有核心竞争力。根据其“人人健康，无人饥饿”的使命，该公司的产品和服务旨在通过支持应对全球人口不断增长和老龄化带来的重大挑战，帮助人们和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros.

拜耳致力于推动可持续发展，并对其业务产生积极影响。与此同时，该集团旨在通过创新和增长来提高其盈利能力和创造价值。拜耳品牌代表着全世界的信任、可靠性和质量。2023财年，该集团雇佣了约10万人，销售额476亿欧元。

R&D expenses before special items amounted to 5.8 billion euros. For more information, go to .

不含特殊项目的研发费用为58亿欧元。有关更多信息，请转至。

www.bayer.com

Find more information at

有关更多信息，请访问

https://pharma.bayer.com

在Facebook上关注我们：

http://www.facebook.com/bayer

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本版本可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来业绩、财务状况、发展或业绩与此处给出的估计之间存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公共报告中讨论的因素，拜耳网站上有这些因素。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担任何责任更新这些前瞻性声明或遵守

them to future events or developments.

他们对未来的事件或发展。

Bayer Global Media Contact

拜耳全球媒体联系人

Malena Johannes, phone +49 173 5470379

Malena Johannes，电话+49 173 5470379